Sepsis and septic shock


State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with an unacceptable high mortality and a significant economic burden to the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000 fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 150,000 patients have been treated with this innovative therapy and more than 250 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function and mortality.

EAA™Endotoxin Activity Assay – is the only FDA approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.


Chronic kidney disease

Filtryzer® PMMA

A personalized therapy based on the individual needs of each patient


Acute respiratory failure


A minimally invasive extracorporeal CO2 removal system for ventilatory support

Focus on



The 36th VICENZA COURSE on AKI and CRRT organized by Professor Claudio Ronco is held in Vicenza 12th–14th June 2018



We are present at the 29th SMART Meeting, 9-11 May 2018 in Milan, the annual meeting in anesthesia and resuscitation in intensive care.

Come and meet us at our booth #30-31.


WORLD KIDNEY DAY – March 8, 2018

World Kidney Day is a global initiative aimed at raising awareness of the importance of our kidneys. In 2018, World Kidney Day coincides with International Women’s Day on March 8, offering the opportunity to highlight the importance of women’s health and particularly their kidney health.